AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
-
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
6/27/2022
AbbVie announced the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of upadacitinib for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs.*
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer
6/24/2022
New insights uncover how patients and caregivers cope emotionally during phases of Chronic Lymphocytic Leukemia (CLL).
-
AbbVie has redeemed a Rare Pediatric Disease Priority Review Voucher for Rinvoq (upadactinib), following its FDA approval for adults with moderately to severely active ulcerative colitis in March.
-
AbbVie Declares Quarterly Dividend - June 23, 2022
6/23/2022
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.41 per share.
-
AbbVie filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for Qulipta for the preventative treatment of migraine.
-
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
6/21/2022
Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTA TM ) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo.
-
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
-
The FDA's decision is based on positive results from two induction and one maintenance clinical study of AbbVie's Skyrizi for Crohn's disease.
-
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
6/17/2022
Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY 1-4.
-
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan AestheticsLicenses Revolutionary Skin Care Compound TFC-1067
6/13/2022
Sirona Biochem Corp. is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.
-
Genmab's Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.
-
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
6/11/2022
AbbVie announced primary results from the large B-cell lymphoma expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating epcoritamab, an investigational subcutaneous bispecific antibody.
-
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
-
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
6/10/2022
AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis, a rare and difficult to treat blood cancer.
-
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
6/10/2022
AbbVie announced five-year follow-up results from the Phase 3 CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of VENCLYXTO®/VENCLEXTA® plus obinutuzumab continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
-
The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.
-
AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
6/7/2022
AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade improved survival rates for people hospitalized with COVID-19 according to a new report by the National Institutes of Health.